{"id":"natalizumab-tysabri","safety":{"commonSideEffects":[{"rate":null,"effect":"Progressive multifocal leukoencephalopathy (PML)"},{"rate":"23","effect":"Headache"},{"rate":"27","effect":"Fatigue"},{"rate":"23","effect":"Infusion reactions"},{"rate":"19","effect":"Arthralgia"},{"rate":"13","effect":"Urinary tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to α4β1 integrin, natalizumab inhibits the adhesion and transmigration of lymphocytes across the blood-brain barrier, reducing immune cell infiltration into the brain and spinal cord. This mechanism reduces inflammation and demyelination in multiple sclerosis and decreases intestinal inflammation in Crohn's disease by preventing leukocyte trafficking to affected tissues.","oneSentence":"Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing them from crossing the blood-brain barrier and entering the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:44.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Crohn's disease (moderate to severe)"}]},"trialDetails":[{"nctId":"NCT02904876","phase":"PHASE4","title":"Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2015-03","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT04821596","phase":"NA","title":"Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2020-07-13","conditions":"Multiple Sclerosis","enrollment":77},{"nctId":"NCT05418010","phase":"PHASE2","title":"Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2022-12-01","conditions":"Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination","enrollment":40},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT05746845","phase":"","title":"Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2023-03-06","conditions":"Healthy, Multiple Sclerosis","enrollment":100},{"nctId":"NCT04178005","phase":"PHASE4","title":"Cladribine Tablets After Treatment With Natalizumab (CLADRINA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2020-02-19","conditions":"Multiple Sclerosis","enrollment":40},{"nctId":"NCT05265728","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Biogen","startDate":"2022-04-26","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":21},{"nctId":"NCT05688436","phase":"","title":"A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies","status":"RECRUITING","sponsor":"Biogen","startDate":"2021-09-24","conditions":"Multiple Sclerosis","enrollment":1178},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT05925049","phase":"","title":"A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2023-06-30","conditions":"Multiple Sclerosis","enrollment":400},{"nctId":"NCT05962177","phase":"NA","title":"Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2023-09-11","conditions":"Multiple Sclerosis","enrollment":400},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT05618301","phase":"PHASE1","title":"Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2023-07-07","conditions":"Sickle Cell Disease","enrollment":10},{"nctId":"NCT05658497","phase":"","title":"Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)","status":"RECRUITING","sponsor":"Biogen","startDate":"2023-10-27","conditions":"Multiple Sclerosis","enrollment":908},{"nctId":"NCT05236777","phase":"","title":"TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-01-01","conditions":"Multiple Sclerosis","enrollment":675},{"nctId":"NCT03193866","phase":"","title":"COMparison Between All immunoTherapies for Multiple Sclerosis.","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2017-06-02","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":3526},{"nctId":"NCT05269888","phase":"","title":"Covid-19 Vaccine Immune Response in Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals of North Midlands NHS Trust","startDate":"2022-02-16","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT03046251","phase":"PHASE4","title":"Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2015-08","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT03811886","phase":"PHASE1, PHASE2","title":"Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Pulmonary Metastatic Osteosarcoma (pOS)","enrollment":""},{"nctId":"NCT06127095","phase":"","title":"A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments","status":"COMPLETED","sponsor":"Biogen","startDate":"2023-11-24","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":474},{"nctId":"NCT06705608","phase":"","title":"Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2003-01-01","conditions":"Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma","enrollment":4000},{"nctId":"NCT05718947","phase":"","title":"Ultra-high-field Brain MRI in Multiple Sclerosis","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2023-09-12","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT05701423","phase":"","title":"A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2023-02-08","conditions":"Multiple Sclerosis","enrollment":34},{"nctId":"NCT03157830","phase":"","title":"Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2017-06-01","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":43},{"nctId":"NCT05532163","phase":"PHASE4","title":"A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"TERMINATED","sponsor":"Biogen","startDate":"2023-01-23","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1},{"nctId":"NCT03689972","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration","status":"COMPLETED","sponsor":"Biogen","startDate":"2018-11-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":585},{"nctId":"NCT00707512","phase":"","title":"CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring","status":"TERMINATED","sponsor":"Biogen","startDate":"2008-06-30","conditions":"Crohn's Disease","enrollment":87},{"nctId":"NCT01706107","phase":"","title":"Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2012-11-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":73},{"nctId":"NCT00771043","phase":"PHASE4","title":"A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2008-11-01","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT02142192","phase":"PHASE2","title":"Natalizumab Subcutaneous Immunogenicity and Safety Study","status":"TERMINATED","sponsor":"Biogen","startDate":"2014-12-01","conditions":"Relapsing Multiple Sclerosis","enrollment":2},{"nctId":"NCT05304520","phase":"","title":"A Study for Tysabri Participant Preference","status":"COMPLETED","sponsor":"Biogen","startDate":"2021-10-12","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS)","enrollment":318},{"nctId":"NCT04472975","phase":"","title":"Prescription Drug Safety and Effectiveness in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"1996-01-01","conditions":"Multiple Sclerosis","enrollment":35000},{"nctId":"NCT05177718","phase":"PHASE4","title":"Natalizumab and Chronic Inflammation","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-09-16","conditions":"Multiple Sclerosis","enrollment":1},{"nctId":"NCT00493298","phase":"","title":"Tysabri Observational Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-06-29","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":6620},{"nctId":"NCT03399981","phase":"","title":"Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-06-01","conditions":"Progressive Multifocal Leukoencephalopathy","enrollment":80327},{"nctId":"NCT04777539","phase":"","title":"Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2021-06-14","conditions":"Multiple Sclerosis (MS)","enrollment":279},{"nctId":"NCT03093064","phase":"PHASE1","title":"Inflammatory Response In Schizophrenia","status":"COMPLETED","sponsor":"King's College London","startDate":"2017-04-01","conditions":"Schizophrenia","enrollment":66},{"nctId":"NCT04565431","phase":"","title":"Examining Effects of Tysabri on Cognitive Fatigue Using fMRI","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2021-03-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":25},{"nctId":"NCT04832399","phase":"","title":"Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-11-12","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":60},{"nctId":"NCT05209815","phase":"","title":"Safety of Exposure to Natalizumab During Pregnancy","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2022-06-20","conditions":"Multiple Sclerosis","enrollment":68},{"nctId":"NCT06159712","phase":"NA","title":"Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2023-11-27","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":200},{"nctId":"NCT00464074","phase":"","title":"Evaluation of Natalizumab for thE Relief of MS Associated FatiGue","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-08-01","conditions":"Multiple Sclerosis","enrollment":89},{"nctId":"NCT04115488","phase":"PHASE3","title":"Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®","status":"COMPLETED","sponsor":"Polpharma Biologics S.A.","startDate":"2019-10-01","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS)","enrollment":265},{"nctId":"NCT05627271","phase":"","title":"The 'Wearing Off' Effect of DMT","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-01-10","conditions":"Multiple Sclerosis","enrollment":39},{"nctId":"NCT04225312","phase":"PHASE4","title":"Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-02-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":300},{"nctId":"NCT04796584","phase":"","title":"Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication","status":"TERMINATED","sponsor":"Providence Health & Services","startDate":"2022-07-11","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT05762003","phase":"","title":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","status":"COMPLETED","sponsor":"IMPULS Endowment Fund","startDate":"2019-01-01","conditions":"Multiple Sclerosis","enrollment":17478},{"nctId":"NCT01970410","phase":"PHASE4","title":"MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2013-10","conditions":"Multiple Sclerosis","enrollment":55},{"nctId":"NCT02769689","phase":"PHASE4","title":"Methylprednisolone During the Switch Between Natalizumab and Fingolimod","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-12","conditions":"Multiple Sclerosis","enrollment":56},{"nctId":"NCT05172466","phase":"NA","title":"Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab","status":"WITHDRAWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-10-31","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":""},{"nctId":"NCT05528666","phase":"","title":"Risk Perception in Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-09","conditions":"Multiple Sclerosis","enrollment":4361},{"nctId":"NCT02133924","phase":"PHASE2","title":"Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"John Levine","startDate":"2016-08","conditions":"Acute Graft Versus Host Disease","enrollment":76},{"nctId":"NCT04834401","phase":"","title":"Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis","status":"COMPLETED","sponsor":"St. Barnabas Medical Center","startDate":"2021-03-22","conditions":"Multiple Sclerosis, Covid19","enrollment":45},{"nctId":"NCT04964700","phase":"","title":"Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab","status":"UNKNOWN","sponsor":"Multiple Sclerosis Center of Northeastern New York","startDate":"2021-05-06","conditions":"Multiple Sclerosis","enrollment":42},{"nctId":"NCT04580381","phase":"","title":"Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2020-09-01","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":500},{"nctId":"NCT04546698","phase":"","title":"5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2020-09-07","conditions":"Multiple Sclerosis, Acute Relapsing, Multiple Sclerosis","enrollment":78},{"nctId":"NCT03135249","phase":"PHASE4","title":"Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-05-01","conditions":"Multiple Sclerosis (MS)","enrollment":9},{"nctId":"NCT03283371","phase":"PHASE2","title":"Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy","status":"COMPLETED","sponsor":"Biogen","startDate":"2018-03-20","conditions":"Epilepsy, Focal Seizures, Partial Seizures","enrollment":67},{"nctId":"NCT04837651","phase":"","title":"Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab","status":"COMPLETED","sponsor":"Dragonfly Research, LLC","startDate":"2021-03-02","conditions":"Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System","enrollment":48},{"nctId":"NCT04048577","phase":"PHASE4","title":"A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab","status":"UNKNOWN","sponsor":"Berkovich, Regina MD, PhD Inc.","startDate":"2019-07-03","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":10},{"nctId":"NCT02440126","phase":"","title":"Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk","status":"COMPLETED","sponsor":"Rocky Mountain MS Research Group, LLC","startDate":"2014-10","conditions":"Multiple Sclerosis","enrollment":196},{"nctId":"NCT01539395","phase":"","title":"A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis","status":"WITHDRAWN","sponsor":"MSDx, Inc.","startDate":"2012-01","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT01541618","phase":"","title":"A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis","status":"COMPLETED","sponsor":"MSDx, Inc.","startDate":"2012-01","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":15},{"nctId":"NCT01981161","phase":"","title":"Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-11-19","conditions":"Multiple Sclerosis","enrollment":307},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT02176031","phase":"PHASE2","title":"Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-01","conditions":"Graft Versus Host Disease","enrollment":21},{"nctId":"NCT02881567","phase":"PHASE3","title":"Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab","status":"TERMINATED","sponsor":"Biogen","startDate":"2017-04-18","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS)","enrollment":41},{"nctId":"NCT04062331","phase":"PHASE1, PHASE2","title":"Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis","status":"UNKNOWN","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2019-10-01","conditions":"Multiple Sclerosis","enrollment":90},{"nctId":"NCT03516526","phase":"PHASE4","title":"Towards Personalized Dosing of Natalizumab in Multiple Sclerosis","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2016-11-03","conditions":"Multiple Sclerosis","enrollment":61},{"nctId":"NCT02965170","phase":"","title":"Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS","status":"COMPLETED","sponsor":"Rocky Mountain MS Research Group, LLC","startDate":"2016-10","conditions":"Multiple Sclerosis","enrollment":109},{"nctId":"NCT02588053","phase":"","title":"Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-07","conditions":"Multiple Sclerosis","enrollment":85},{"nctId":"NCT01658384","phase":"","title":"Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Clinique Neuro-Outaouais","startDate":"2011-09","conditions":"Multiple Sclerosis","enrollment":63},{"nctId":"NCT01485003","phase":"","title":"Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-02-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":231},{"nctId":"NCT02730455","phase":"PHASE2","title":"Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-07-18","conditions":"Acute Ischemic Stroke","enrollment":277},{"nctId":"NCT02677077","phase":"","title":"Clinical Disease Activity With Long Term Natalizumab Treatment","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-12-31","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":277},{"nctId":"NCT00884481","phase":"","title":"Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-03-23","conditions":"Relapsing-Remitting Multiple Sclerosis, Fatigue","enrollment":195},{"nctId":"NCT02386566","phase":"","title":"Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-03-20","conditions":"Multiple Sclerosis","enrollment":48},{"nctId":"NCT02846558","phase":"NA","title":"A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2016-08","conditions":"Multiple Sclerosis","enrollment":54},{"nctId":"NCT01943526","phase":"","title":"Ireland Natalizumab (TYSABRI) Observational Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2011-11-30","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":191},{"nctId":"NCT02383550","phase":"","title":"Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension","status":"COMPLETED","sponsor":"Clinique Neuro-Outaouais","startDate":"2014-12","conditions":"Multiple Sclerosis","enrollment":46},{"nctId":"NCT01071512","phase":"NA","title":"Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2010-04","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT01416181","phase":"PHASE3","title":"A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis","status":"TERMINATED","sponsor":"Biogen","startDate":"2011-09-13","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":889},{"nctId":"NCT02342704","phase":"PHASE4","title":"Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2014-11-30","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":111},{"nctId":"NCT02241785","phase":"PHASE4","title":"Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies","status":"TERMINATED","sponsor":"Biogen","startDate":"2014-09-30","conditions":"Relapsing Multiple Sclerosis","enrollment":47},{"nctId":"NCT01455220","phase":"NA","title":"The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2011-01","conditions":"Multiple Sclerosis","enrollment":45},{"nctId":"NCT00306592","phase":"PHASE3","title":"Natalizumab Re-Initiation of Dosing","status":"COMPLETED","sponsor":"Biogen","startDate":"2006-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":404},{"nctId":"NCT00871780","phase":"PHASE4","title":"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-08","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":224},{"nctId":"NCT00536120","phase":"PHASE4","title":"The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2008-01","conditions":"Multiple Sclerosis","enrollment":60},{"nctId":"NCT02483845","phase":"PHASE1","title":"Natalizumab in Inclusion Body Myositis (IBM)","status":"UNKNOWN","sponsor":"Phoenix Neurological Associates, LTD","startDate":"2013-05","conditions":"Inclusion Body Myositis (IBM)","enrollment":6},{"nctId":"NCT00027300","phase":"PHASE3","title":"Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2001-11","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT01710228","phase":"PHASE2","title":"Alternative Treatment Paradigm for Natalizumab Trial","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-07","conditions":"Multiple Sclerosis (MS)","enrollment":""},{"nctId":"NCT02142764","phase":"NA","title":"Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-11","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT01070823","phase":"","title":"JC-Virus (JCV) Antibody Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-03","conditions":"Multiple Sclerosis","enrollment":1096},{"nctId":"NCT01070836","phase":"","title":"JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-03","conditions":"Relapsing Multiple Sclerosis","enrollment":35895},{"nctId":"NCT02277964","phase":"","title":"Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2012-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":25},{"nctId":"NCT00083759","phase":"PHASE2","title":"Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate","status":"TERMINATED","sponsor":"Biogen","startDate":"2004-05","conditions":"Rheumatoid Arthritis","enrollment":299},{"nctId":"NCT00297232","phase":"PHASE3","title":"Natalizumab (Tysabri) Re-Initiation of Dosing","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-03","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1094},{"nctId":"NCT01955707","phase":"PHASE2","title":"Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-01","conditions":"Acute Ischemic Stroke","enrollment":161},{"nctId":"NCT01884935","phase":"PHASE1","title":"PK and PD Study of Natalizumab in Pediatric Subjects With RRMS","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":13},{"nctId":"NCT00801125","phase":"PHASE4","title":"Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"PYREXIA"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ACUTE PRERENAL FAILURE"},{"count":1,"reaction":"ADRENAL INSUFFICIENCY"},{"count":1,"reaction":"ADRENOCORTICAL INSUFFICIENCY ACUTE"},{"count":1,"reaction":"BRADYCARDIA"},{"count":1,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":1,"reaction":"CONVULSION"},{"count":1,"reaction":"CYTOMEGALOVIRUS INFECTION"}],"_approvalHistory":[],"publicationCount":116,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Natalizumab (Tysabri)","genericName":"Natalizumab (Tysabri)","companyName":"Cornerstone Health Care, PA","companyId":"cornerstone-health-care-pa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Natalizumab blocks the α4β1 integrin on immune cells, preventing them from crossing the blood-brain barrier and entering the central nervous system. Used for Relapsing-remitting multiple sclerosis, Crohn's disease (moderate to severe).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}